Notification on the commencement of a Phase III clinical study of HP-3000 in Japan
(a transdermal drug for the treatment of Parkinson's disease)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; President and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces that Hisamitsu has commenced a Phase III clinical study for a transdermal drug for the treatment of Parkinson's disease in Japan (Development code: HP-3000, Active pharmaceutical ingredient: ropinirole hydrochloride, hereinafter referred to as “the product”).

In the Phase III clinical study, the efficacy and safety of administration of the product once per day will be compared with a placebo and with a positive drug (oral drug) in patients with Parkinson’s disease who concomitantly use L-dopa (levodopa).

The product is a transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. We expect the product to be a new option for the treatment of Parkinson’s disease by realizing its long-lasting effect by means of maintaining a stable blood concentration.

A Phase III long-term clinical study of the product was commenced in last December for Parkinson’s disease.

In the future, we aim to apply for manufacturing and marketing approval during FY 2017.